Human Pathology
Volume 41, Issue 6 , Pages 815-823 , June 2010

Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression

  • Béma Coulibaly, MD

      Affiliations

    • Département d'Anatomie Pathologie et de Neuropathologie, Centre Hospitalier Universitaire (CHU) Timone, 13005 Marseille, France
    • Laboratoire d'Angiogénèse, Invasion et Micro-environnement tumoral, Inserm Unité Mixte de Recherche (UMR) 911, Faculté de Médecine Timone, 13385 Marseille cedex 05, France
    • Corresponding Author InformationCorresponding author. Département de Neuropathologie, CHU Timone, 13005 Marseille, France.
    • ,
  • Isabelle Nanni, PharmD

      Affiliations

    • Laboratoire de transfert d'Oncologie Biologique, Faculté de Médecine Nord, 13016 Marseille, France
    • ,
  • Benoit Quilichini, MD

      Affiliations

    • Laboratoire d'Angiogénèse, Invasion et Micro-environnement tumoral, Inserm Unité Mixte de Recherche (UMR) 911, Faculté de Médecine Timone, 13385 Marseille cedex 05, France
    • ,
  • Jean Gaudart, MD, PhD

      Affiliations

    • Unité Fonctionnelle (UF) Biostatistique et Méthodologie de la Recherche Clinique, Service de Santé Publique et d'Information Médicale (SSPIM)/ Laboratoire d'Enseignement et de Recherche sur le Traitement de l'Information Médicale (LERTIM), CHU Timone, 13005 Marseille, France
    • ,
  • Philippe Metellus, MD

      Affiliations

    • Département de Neurochirurgie, CHU Timone, 13005 Marseille, France
    • ,
  • Frédéric Fina, PhD

      Affiliations

    • Laboratoire de transfert d'Oncologie Biologique, Faculté de Médecine Nord, 13016 Marseille, France
    • ,
  • Céline Boucard, MSc

      Affiliations

    • Département de Neuro-Oncologie, CHU Timone, 13005 Marseille, France
    • ,
  • Olivier Chinot, MD

      Affiliations

    • Département de Neuro-Oncologie, CHU Timone, 13005 Marseille, France
    • ,
  • L'Houcine Ouafik, PhD

      Affiliations

    • Laboratoire d'Angiogénèse, Invasion et Micro-environnement tumoral, Inserm Unité Mixte de Recherche (UMR) 911, Faculté de Médecine Timone, 13385 Marseille cedex 05, France
    • ,
  • Dominique Figarella-Branger, MD, PhD

      Affiliations

    • Département d'Anatomie Pathologie et de Neuropathologie, Centre Hospitalier Universitaire (CHU) Timone, 13005 Marseille, France
    • Laboratoire d'Angiogénèse, Invasion et Micro-environnement tumoral, Inserm Unité Mixte de Recherche (UMR) 911, Faculté de Médecine Timone, 13385 Marseille cedex 05, France

Received 28 April 2009 ,Revised 4 August 2009 ,Accepted 10 September 2009.

References 

  1. Torp SH, Gulati S, Johannessen E, Dalen A. Coexpression of c-erbB 1-4 receptor proteins in human glioblastomas. An immunohistochemical study. J Exp Clin Cancer Res. 2007;26:353–359
  2. Huncharek M, Kupelnick B. Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol Res. 2000;12:107–112
  3. Batchelor TT, Betensky RA, Esposito JM, et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res. 2004;10:228–233
  4. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003;63:6962–6970
  5. Simmons ML, Lamborn KR, Takahashi M, et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res. 2001;61:1122–1128
  6. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93:1246–1256
  7. Houillier C, Lejeune J, Benouaich-Amiel A, et al. Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer. 2006;106:2218–2223
  8. Layfield LJ, Willmore C, Tripp S, Jones C, Jensen RL. Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors. Appl Immunohistochem Mol Morphol. 2006;14:91–96
  9. Donato V, Papaleo A, Castrichino A, et al. Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide. Tumori. 2007;93:24–256
  10. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012–2024
  11. de Groot JF, Gilbert MR, Aldape K, et al. Study of carboplatin and erlotinib (Tarceva, OSI 774) in patients with recurrent glioblastoma. J Neurooncol. 2008;90:89–97
  12. Viana-Pereira M, Lopes JM, Little S, et al. Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas. Anticancer Res. 2008;28:913–920
  13. Schlegel J, Merdes A, Stumm G, et al. Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer. 1994;56:72–77
  14. Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A. 1992;89:4309–4313
  15. Hirsch FR, Varella-Garcia M, Bunn PA, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798–3807
  16. Martens T, Laabs Y, Gunther HS, et al. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor–2. Clin Cancer Res. 2008;14:5447–5458
  17. Andersson U, Johansson D, Behnam-Motlagh P, Johansson M, Malmer B. Treatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitro. Acta Oncol. 2007;46:951–960
  18. Combs SE, Schulz-Ertner D, Roth W, Herold-Mende C, Debus J, Weber KJ. In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab. Int J Radiat Oncol Biol Phys. 2007;68:873–882
  19. Franceschi E, Cavallo G, Lonardi S, et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro Oncologia (GICNO). Br J Cancer. 2007;96:1047–1051
  20. Mellinghoff IK, Cloughesy TF, Mischel PS. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2007;13:378–381
  21. Voelzke WR, Petty WJ, Lesser GJ. Targeting the epidermal growth factor receptor in high-grade astrocytomas. Curr Treat Options Oncol. 2008;9:23–31

☆ This study has been reviewed by the relevant institutional review board (University of Aix-Marseille) and has been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. All patients gave their informed consent prior to their inclusion in the study.

☆☆ This work was supported by INCA (RS 019, gliother; Paris, France), by the PACA Canceropole (Marseille, France), by INSERM grants to CRO2 UMR 911 (Marseille, France), by Lionel Perrier Foundation (Montreux, Switzerland), and by the GEFLUC (Marseille, France).

★ Disclosure of funding: none.

★★ The authors declare that they have no conflict of interest.

PII: S0046-8177(09)00462-6

doi: 10.1016/j.humpath.2009.09.020

Human Pathology
Volume 41, Issue 6 , Pages 815-823 , June 2010

Article Tools

* Image Usage & Resolution